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Introduction
Despite relevant improvements in the treatment of 
 respiratory failure, above all low tidal ventilation, severe 
acute respiratory distress syndrome (ARDS) continues 
to have a high mortality rate1. The etiology of ARDS can 
be classified as primary lung insult caused by bacterial, 
viral, or aspiration pneumonia, or other primary lung 
disease, or secondary lung injury as a result of shock, 
trauma, sepsis, or other systemic conditions2.
Modern extracorporeal membrane oxygenation 
(ECMO) currently establishes a place in the treatment of 
acute severe respiratory failure with presumed improved 
survival3–5. Over the last decade, technical improvements 
in ECMO equipment, including centrifugal pumps, 
 polymethylpentene (PMP) oxygenators, percutaneous 
cannulation techniques and heparin-coated circuits, have 
reduced procedure-related complications4. Implantation 
of ECMO at the referring hospitals and the transport of 
these patients on ECMO to an institution with expertise is 
a logistic challenge with a high potential for complications. 
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Background: Over the last decade, technical improvements in extracorporeal membrane oxygenation (ECMO) equipment 
have reduced procedure-related complications and have made ECMO an effective option for patients with acute 
respiratory distress syndrome (ARDS) if conventional therapy fails.
Methods: In this report, we present our early experience with the Cardiohelp, a new portable miniaturized ECMO 
system, in 22 consecutive patients with ARDS. All patients were placed on venovenous ECMO. Cannulas were inserted 
percutaneously, employing the Seldinger technique. Data were collected prospectively.
Results: The median patient age was 47 years (36 to 61). Fifteen patients from regional hospitals were too unstable for 
conventional transport and were placed on Cardiohelp at the referring hospital and then transported to our institution. 
The patients were transported by ambulance (n=2) or helicopter (n=13) over a distance of 50-250 km. Cardiohelp 
support resulted in immediate improvement of gas exchange and highly protective ventilation. The median duration of 
support was 13 days (8 to 19). An exchange of the device was necessary in 9 patients. Sixteen patients (72.7%) were 
successfully weaned from ECMO and fifteen patients (68.2%) survived. Device-related complications were not observed.
Conclusions: The compact portable ECMO device Cardiohelp is a highly effective method to secure vital gas exchange and 
to reduce further ventilator-induced lung injury in patients with acute respiratory failure. Crucial technical innovations and 
ease of device transport and implantation allow location-independent stabilization with consecutive inter-hospital transfer.
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Hence, development of a compact, portable device to sup-
port and transport patients with severe respiratory failure 
is needed.
Recently, the new miniaturized ECMO system 
Cardiohelp (Maquet Cardiopulmonary, Hirrlingen, 
Germany) for severe cardiopulmonary failure has been 
developed and marketed. The small size of this device, 
with reduced foreign surface combined with BIOLINE 
coating (Maquet Cardiopulmonary), a plasma resistant 
membrane and improved pump technology decreases 
the need for systemic anticoagulation. In clinical prac-
tice, an additional advantage of this ECMO system is the 
integrated sensor technology for measurement of in-line 
pressures, blood temperature, hemoglobin concentra-
tion and venous saturation.
In this report, we present our experience with the new 
miniaturized system, Cardiohelp, in the first 22 patients 
with severe respiratory failure.
Patients and Methods
Between May 2010 and July 2011, we treated 22 ARDS 
patients with the new system in a veno-venous mode. 
Twenty patients were supported from the beginning with 
the Cardiohelp system. Two patients were initially sup-
ported with another ECMO system. An exchange of their 
device was necessary due to circuit thrombus formation. 
Data collection was performed prospectively.
Before patients were considered potential candidates 
for ECMO, their clinical course was carefully evaluated. 
This included optimization of volume status and vasoac-
tive agent requirements, lung protective ventilation with 
low tidal volumes, moderate hypercapnia, and high posi-
tive end-expiratory pressure (PEEP), the use of adjunc-
tive therapeutic measures such as prone position or nitric 
oxide, as well as treatment of the underlying disease in 
accordance with standard intensive care procedures6.
Patients from regional hospitals who were potential 
candidates for ECMO were transferred to our center. If 
the patients were too unstable for conventional trans-
port, they were placed on Cardiohelp at the referring 
hospital and then transported to our institution. The 
transport team included a cardiovascular surgeon and/
or an experienced anesthesiologist, a perfusionist and a 
nurse or paramedic. For ground transport, a special 
intensive care transport vehicle was used. For air medical 
transport, a rescue helicopter was available7.
The Cardiohelp system (CE licensed for use of 30 days 
in Europe) consists of a centrifugal pump with an inte-
grated battery for transport and a performance of up to 
7 L/min, a polymethylpentene (PMP) diffusion mem-
brane oxygenator, which avoids plasma leakage and has a 
total gas exchange surface of 1.8 m2, with a low inherent 
resistance, and two cannulas. The priming volume of the 
complete device was 600 mL. An additional advantage of 
this ECMO system is the integrated sensor technology 
for measurement of venous oxygen saturation, hemo-
globin, hematocrit and arterial blood temperature. 
Furthermore, the continuous analysis of in- and out-
flow pressures is displayed (Figure 1). Weighing about 
10 kg, the Cardiohelp system can be carried comfortably 
during transport.
All cannulas were inserted percutaneously, employing 
the Seldinger technique. For outflow, usually, the right 
femoral vein was cannulated with a long 21 – 23 Fr sin-
gle-stage cannula (BE-PVS, Maquet Cardiopulmonary). 
For reinfusion, a short 15 – 17 Fr cannula was used, 
which was usually implanted in the right internal jugular 
vein. Six patients were supported using an internal jugu-
lar vein insertion of the Avalon Elite bicaval, dual-lumen 
cannula 25 – 27 Fr (Avalon Laboratories, Rancho 
Dominguez, CA, USA).
Post-dilatation prior to cannula implantation, all 
patients received an intravenous single dose of heparin 
of 1,000 – 5,000 IU. Systemic anticoagulation was given 
by continuous infusion of standard heparin. The effect 
of heparin was measured via the activated partial throm-
boplastin time (aPTT). As the whole system had a bio-
compatible BIOLINE coating, a pronounced systemic 
Figure 1. Patient on active extracorporeal membrane 
oxygenation, Cardiohelp. The outflow cannula is inserted in the 
right femoral vein and advanced into the right internal jugular.
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anticoagulation was not necessary and an aPTT 1.5 times 
normal was considered sufficient (aPTT 50 – 60s). 
Additionally, 100 mg/day of acetylsalicylic acid were usu-
ally given to inhibit platelet aggregation. Oxygen was 
used as the sweep gas, with a flow of 1-12 L/min.
After implementation of the ECMO, invasiveness of 
mechanical ventilation was immediately reduced to 
diminish further ventilator-induced lung injury (VILI). 
Accordingly, tidal volume, minute ventilation, inspira-
tory pressure (PIP) and fraction of inspired oxygen 
(FiO2) were decreased (typically FiO2<0.5, PIP<27 cm 
H2O). PEEP was not initially reduced to avoid atelectasis 
due to small tidal volume5.
After weaning and removal of the cannulas, hemosta-
sis was achieved with manual compression of the groin 
and neck.
Statistical analysis
The statistical analysis was performed using the SPSS 
18.0 software (SPSS, Chicago, IL, U.S.A.). Normal distri-
bution was assessed by the Lilliefors Modification of the 
Kolmogorov-Smirnov test. Values of continuous data are 
presented as mean ± standard deviation (SD) or as the 
median, with interquartile range when appropriate. 
Statistical significance was considered when p<0.05.
Results
A total of 22 patients with severe acute respiratory failure 
were treated with the new miniaturized device, Cardiohelp 
(Table 1). The cohort consisted of 4 women and 18 men, 
with a median age of 47 years (36 to 61). Causes of severe 
respiratory failure were: pneumonia in 14 patients, mul-
tiple trauma or post-surgery in 5 patients, and influenza 
A (H1N1) infection in 3 patients. The median Sequential 
Organ Failure Assessment (SOFA) score was 9 (7 to 13) 
and the median Lung Injury Score (LIS) was 3.50 (3.33 to 
3.67). Seven patients were successfully supported with 
Cardiohelp at our center. Fifteen patients from regional 
hospitals were too unstable for conventional transport, 
and were placed on ECMO at the referring hospital and 
then transported to our institution. The median duration 
of ventilation before ECMO was 1 day (1 to 3). One 
patient was non-invasively ventilated without mechanical 
ventilation; the ECMO was implanted to avoid invasive 
ventilation after a post-pneumonectomy bronchopleural 
fistula. Sixteen patients were cannulated by the conven-
tional technique (right femoral vein to right internal jug-
ular or right subclavian vein). Six patients were supported 
using internal jugular vein insertion of the newly devel-
oped Avalon Elite bicaval dual-lumen cannula.
Table 3 summarizes changes in arterial blood 
gases, arterial pH, inotropic support, and mean arterial 
 pressure over time. Arterial blood gas analyses prior to 
implantation revealed a PaO2/FiO2 ratio of 60 mmHg 
(46 to 75), a PaCO2 of 67 mmHg (57 to 100) and a pH 
level of 7.23 (7.17 to 7.32). Two hours after implantation, 
the PaO2/FiO2 ratio, PaCO2 and pH levels had signifi-
cantly improved to 123 mmHg (94 to 156), 34 mmHg 
(31 to 39) and 7.49 (7.41 to 7.54) (p< 0.05). Also, the 
mean arterial pressure (MAP) increased from 69 mmHg 
(63 to 77) to 79 mmHg (72 to 89) (p<0.05), despite a 
notable reduction in the norepinephrine dose from 1.5 
mg/h (0.4 to 4.3) to 1 mg/h (0.4 to 3.2) (p<0.05). Blood 
flow through the device averaged 3.1 L/min (2.7 to 3.4) 
initially. After implementation of the Cardiohelp, the 
ventilation parameters (tidal volume, PIP and FiO2) 
could be significantly reduced towards more protective 
ventilation.
The median duration of support was 13 days (8 to 19). 
Four patients on ECMO were successfully weaned from 
mechanical ventilation. After weaning, the median dura-
tion of continued ventilation was 6 days (3 to 11). Sixteen 
patients were successfully weaned from ECMO and fif-
teen patients (68.2%) survived. Six patients died of mul-
tiple organ failure and sepsis while on ECMO. One patient 
died of multiple organ failure 49 days after weaning. 
Table 1. Patient data and characteristics before ECMO support
n = 22
Age, years 47 (36 to 61)
Male (%) 18 (81.8)
BMI, kg/m2 31 ± 8
Diagnosis leading to ARDS (%)
 Pneumonia 14 (63.6)
 Trauma/Post-surgery 5 (22.7)
 H1N1 3 (13.7)
SOFA score 9 (7 to 13)
LIS score 3.5 (3.33 to 3.67)
Mechanical ventilation, days 1 (1 to 3)
Acute renal failure (%) 3 (13.7)
ARDS = acute respiratory distress syndrome; ECMO = extracorporeal 
membrane oxygenation; H1N1 = Influenza A infection; LIS = lung injury 
score; SOFA = sequential organ failure assessment score
Table 2. Overview of ECMO and patient outcome
n = 22
Transport on ECMO (%) 15 (68.2)
ECMO duration, days 13 (8 to 19)
Ventilation after ECMO, days 6 (3 to 11)
Weaning (%) 16 (72.7)
Survival (%) 15 (68.2)
Blood transfusion 13 (59.1)
Device exchange 9 (40.9)
Device-related complications (%) 0 (0)
ECMO = extracorporeal membrane oxygenation
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Acute renal failure during support was observed in three 
patients and two of these patients died on ECMO.
Laboratory values before, during and after ECMO sup-
port are presented in Table 3. Hemoglobin levels and 
platelet counts dropped during ECMO support (p<0.05). 
The plasma free hemoglobin level as a marker of hemoly-
sis was not significantly altered by ECMO (Table 3). 
Thirteen patients required red blood cell (RBC) transfu-
sion during Cardiohelp support. Transfusion require-
ments averaged 0.3 units (0.1 to 0.4) of RBC per day. Five 
patients required platelet transfusion and only three 
patients required fresh frozen plasma (FFP) transfusion.
Technical problems that could not be controlled or 
other device-related complications with an adverse effect 
on outcome were not observed. On-line measurement 
failed in 5 patients after 3 - 7 days. An exchange of the 
device was necessary in 9 patients due to circuit throm-
bus formation, which results in an average device time of 
9 ± 5 days (Figure 2). Although aPTT was between 50 
and 60 sec, which was the target level, the flow resistance 
increased significantly at 3.0 L/min. Membrane oxygen-
ator (MO) replacement criteria were the appearance of 
reduced CO2 elimination and oxygenation transfer 
capacity, which were considered to be the consequence 
of thrombotic deposits on the gas exchange capillaries. A 
further criterion was an increase in blood flow resistance 
with a pressure decline (dpMO = pMO in – pMO out) 
across the MO of more than 70 mmHg at a blood flow of 
3 L/min, indicating the necessity for replacement of the 
device8.
Infections associated with the system and/or cannulas 
were not observed. As the reason of acute deterioration 
in most patients was an infectious complication, all 
patients had been on broad-spectrum antibiotic treat-
ment prior to support.
Comment
Despite improvements in ventilation support techniques, 
lung protection strategies and the application of new 
support treatment, ARDS continues to have a high mor-
tality rate1. ECMO is accepted as a standard-of-care for 
neonates and children with progressive respiratory and/or 
cardiac failure refractory to conventional management9. 
In contrast, adult ECMO was confined to specialized 
centers and reserved for exceptional cases due to high 
complication rates (bleeding, thrombosis, hemolysis, 
severe infection, and renal insufficiency), increased cost 
and logistics, but also because of disappointing results 
from historic randomized trials10,11.
Meanwhile, several technical improvements have 
occurred. The first important technical advance was the 
development of a new generation of centrifugal pumps. 
In comparison with traditional roller pumps, the cen-
trifugal pump has virtually no risk of tubing rupture or 
spallation; it has a smaller priming volume, it does not 
Table 3. Changes in blood gases, hemodynamics and laboratory variables.
pre ECMO  
(n = 22)
2 hours  
(n = 22)
Day 1  
(n = 22)
Day 2  
(n = 22)
End of ECMO  
(n = 16)
Day 1 after ECMO 
(n = 16)
PaO2/FiO2 
(mmHg)
60 
(46 to 75)
123* 
(94 to 156)
153* 
(102 to 220)
158* 
(126 to 195)
265* 
(215 to 318)
230* 
(160 to 274)
PaCO2  
(mmHg)
67 
(57 to 100)
34* 
(31 to 39)
37* 
(35 to 43)
43* 
(39 to 45)
42* 
(37 to 42)
41* 
(37 to 50)
pH 7.23 
(7.17 to 7.32)
7.49* 
(7.41 to 7.54)
7.48* 
(7.43 to 7.49)
7.44* 
(7.43 to 7.45)
7.42* 
(7.39 to 7.49)
7.43* 
(7.35 to 7.44)
MAP (mmHg) 69 
(63 to 77)
79* 
(72 to 89)
78* 
(67 to 83)
81* 
(76 to 85)
88* 
(76 to 95)
81* 
(72 to 86)
Norepinephrine 
(mg/h)
1.5 
(0.4 to 4.3)
1.0* 
(0.4 to 3.2)
0.7* 
(0.3 to 1.2)
0.2* 
(0.0 to 0.6)
0.0* 
(0.0 to 0.0)
0.0* 
(0.0 to 0.0)
ECMO flow  
(L/min)
– 3.1 
(2.7 to 3.4)
2.7 
(2.5 to 3.1)
2.6 
(2.4 to 2.9)
1.5 
(1.4 to 1.6)
–
Hemoglobin  
(g/dL)
11.1 
(9.1 to 12.3)
10.3 
(9.4 to 11.3)
9.9* 
(9.2 to 10.9)
9.5* 
(9.0 to 10.1)
8.7* 
(8.1 to 9.2)
9.2* 
(8.1 to 9.6)
Free Hb  
(mg/L)
39 
(30 to 163)
40 
(30 to 123)
54 
(31 to 91)
52 
(31 to 72)
58 
(34 to 102)
48 
(30 to 83)
Platelets  
(/nL)
207 
(108 to 298)
175 
(86 to 277)
159* 
(86 to 243)
127* 
(91 to 235)
119* 
(99 to 166)
123* 
(102 to 182)
Lactic acid  
(mg/dL)
23
(15 to 36)
30
(16 to 49)
20
(16 to 30)
16* 
(12 to 24)
11* 
(9 to 17)
11* 
(7 to 12)
* = p<0.05 to first measurement; ECMO = extracorporeal membrane oxygenation; FiO2 = fraction of inspired oxygen; Hb = hemoglobin;  
MAP = mean arterial pressure; PaCO2 = partial pressure of carbon dioxide in arterial blood; PaO2 = Partial pressure of oxygen in arterial blood
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require the use of a reservoir, and it has an equivalent low 
incidence of hemolysis12. The introduction of heparin-
coated circuits has led to reduced platelet activation, 
reduced complement activation, reduced granulocyte 
activation, and greatly reduced heparin requirements13. 
In contrast to silicone membrane oxygenators, the poly-
methylpentene oxygenator has reduced red blood cell 
and platelet transfusion requirements, better gas 
exchange, lower resistance, lower priming volume and an 
incorporated heat exchanger. In comparison to polypro-
pylene microporous oxygenators, the PMP oxygenator 
has a reduced rate of oxygenator failure14.
In this report, we present our early experience with 
the new portable miniaturized ECMO system, 
Cardiohelp, for severe respiratory failure in adults. 
Implantation of the device led to a rapid and sustained 
improvement of blood gases and a correction of respira-
tory acidosis with hemodynamic stabilisation. Our data 
are of particular interest because 68% of the patients 
were successfully weaned and survived, and also because 
the typical complications related to ECMO support, 
such as bleeding, thrombosis, and severe infection, were 
very limited, despite a high SOFA score and long support 
duration (up to 46 days)4,5. With the new device, we did 
not encounter mechanical complications that were life 
threatening. In particular, rupture of the tubing or leak-
age of the oxygenator did not occur. Oxygenator failure 
was exclusively a result of slowly progressing thrombotic 
occlusion. An exchange of the device was necessary in 9 
patients due to circuit thrombus formation, which 
resulted in an average device time of 9 days. Mueller et al. 
demonstrated similar results with another miniaturized 
ECMO system5. As the whole system has a biocompatible 
BIOLINE coating, a pronounced systemic anticoagula-
tion was unnecessary without any thromboembolic 
complications. This decreased the rate of blood transfu-
sions, which had been considerably higher in previous 
studies, despite the fact that the current study included 
patients with multiple trauma and thrombocytope-
nia15,16. The rate of hemorrhagic complications was 
markedly reduced, which makes its implementation pos-
sible in patients with a risk of bleeding, which had been 
traditionally contraindications for ECMO therapy. The 
plasma free hemoglobin level as a marker of hemolysis 
was not significantly altered by ECMO.
Patients from regional hospitals who were potential 
candidates for ECMO were transferred to our center. If the 
patients were too unstable for conventional transport, 
they were placed on Cardiohelp at the referring hospital 
and then transported to our institution. The Cardiohelp 
system is light enough to be carried by one person and 
compact enough for transport in a helicopter or vehicle. 
The integrated rechargeable battery provides 90 minutes 
of operation without an external power supply. In its most 
complete configuration, the Cardiohelp permits monitor-
ing of all important blood parameters during support for 
cardiac and/or respiratory assistance. Thus, the portable 
system assumes the function of the heart and/or lungs, 
ensuring that the patient receives adequate oxygen and has 
a stable circulation during inter- and intra-hospital trans-
port. Complexity and hazards of inter- and intra-hospital 
transfer could be reduced with the Cardiohelp system.
However, the Cardiohelp device has some disadvan-
tages. The device cost is relatively high compared to other 
Figure 2. Overview of Cardiohelp exchange rate.
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ECMO system. The exchange of faulty components 
(oxygenator or blood pump) is not possible and an 
exchange of the complete unit is necessary. During long-
term support, on-line measurement failed in some cases 
after a few days.
Our report has a few limitations. The report is a sin-
gle-center experience, the patient sample is low and a 
comparison with other devices is lacking.
In conclusion, Cardiohelp is also an effective, compact 
ECMO device in acute respiratory failure of adults. It 
helps to secure vital gas exchange and to reduce further 
ventilator-induced lung injury. Due to its design, moni-
toring and transport of ECMO patients is facilitated.
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